Business Wire

Lumicell’s LumiSystem™ Featured on Viewpoint with Dennis Quaid for New Episode on Fluorescence-Imaging Guidance During Lumpectomy Surgery

NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is ...
Business Wire

Lumicell™ DVS Pivotal Trial Results Published in NEJM Evidence and to Be Presented at ASBrS Assess Safety and Effectiveness of System for Identifying Residual Breast Cancer ...

INSITE Trial included more than 400 patients at 14 leading academic and community cancer centers Intracavity visualization system uses fluorescence imaging designed to identify residual cancer and ...
MedPage Today

FDA Greenlights Imaging Agent to Detect Residual Cancer After Lumpectomy

The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...
Seattle Times

More breast cancer patients can choose smaller surgery

Many women with two or three breast tumors can get by with lumpectomy surgery instead of having their whole breast removed, a new study suggests. In recent years, more patients with multiple tumors ...